Drug · Monoclonal Antibody

Rituximab

CI-DRUG-00000703Explore in graph →CHEMBL1201576 Approved

Regulatory

Approvals (37)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory37 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as RIABNI (DIN 02513447) under ATC L01FA01 RITUXIMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Oct 10, 2024	Apr 21, 2021	health-canada-dpd
CA Health Canada	—	Marketed in Canada as RUXIENCE (DIN 02495724) under ATC L01FA01 RITUXIMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 26, 2020	health-canada-dpd
CA Health Canada	—	Marketed in Canada as RIXIMYO (DIN 02498316) under ATC L01FA01 RITUXIMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 22, 2020

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 18 hours agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	335	143	247	1,358	37	CA, EU, US	Nov 26, 1997	May 8, 1993
Non-Hodgkin Lymphoma	Approved	Phase 4	226	93	148	743	2	EU, US	Nov 26, 1997	May 8, 1993
Leukemia	Phase4	Phase 4	61	30	44	307	0	—	—	1997-09
Malignant Central Nervous System Neoplasm	Phase3	Phase 3	16	10	1	35	0

Curated evidence

Clinical evidence (0)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

Data not yet available

No curated evidence item mentions this therapy yet.

Clinical trials

Trials with this intervention (1,384)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 1,384 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00092222	Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity	active not recruiting	Phase 2	75	National Cancer Institute (NCI)NIH	1	Sep 28, 2026	clinicaltrials
NCT02180711	Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma	active not recruiting

Molecule

Record

Kind: Monoclonal Antibody
Mechanism: B-lymphocyte antigen CD20 binding agent
Targets: 1 gene
UNII: 4F4X42SYQ6
Aliases: ABP-798, ABP798, ADRUXE, Bi 695500, BI695500, Blitzima, CT-P10, Gp2013, GP-2013, HS-006, HS006, HS-006 (RITUXIMAB BIOSIMILAR), IDEC-102, IDEC102, IDEC-C 2B8, IDEC-C2B8, Ituxredi, MabThera, Mabthera rituxan, Mk-8808, Pf-05280586, R-105 IDEC-102, RG-105, RHCACD20MA, Riabni, RIABNI, Ritemvia, RITUXAN, Rituximab, Rituximab abbs … (+25)

Data updated 2 days agoSource updated unknown

Identifiers

Codes (29)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01FA01	RITUXIMAB
ATC (WHO)	L01XC02	Antineoplastic agents